Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Bandekar, R"'
Autor:
Fizazi, K., De Bono, J.S., Flechon, A., Heidenreich, A., Voog, E., Davis, N.B., Qi, Ming, Bandekar, R., Vermeulen, J.T., Cornfeld, M., Hudes, G.R.
Publikováno v:
In European Journal of Cancer 2012 48(1):85-93
Autor:
Brighton, TA, Khot, A, Harrison, SJ, Ghez, D, Weiss, BM, Kirsch, A, Magen, H, Gironella, M, Oriol, A, Streetly, M, Kranenburg, B, Qin, X, Bandekar, R, Hu, P, Guilfoyle, M, Qi, M, Nemat, S, Goldschmidt, H
Publikováno v:
Clinical Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Purpose: IL6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL6 with siltuximab to delay the transition from high-risk smoldering multiple myeloma (SMM) to multiple myeloma. Patients and Methods: In a randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::68a8dccb1911b5fae6ed7c9a4102d214
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3125
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3125
Autor:
Scheiman, J. M.1,2 (AUTHOR), Bandekar, R. R.1 (AUTHOR), Chernew, M. E.1,3 (AUTHOR), Fendrick, A. M.1,3 (AUTHOR)
Publikováno v:
Alimentary Pharmacology & Therapeutics. Jan2001, Vol. 15 Issue 1, p63-71. 9p.
We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::d6b16078f765a2629dea44aab1896795
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3110361
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3110361
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Grunberg, S M, Russo, M W, Bandekar, R, Wright, O, Camlett, I & Herrstedt, J 2008, ' Phase III Results of a single oral and a 3-day iv/oral dosing regimen of the novel Neurokinin-1 (NK-1) receptor antagonist, casopitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) ', Annals of Oncology, no. Supplement 8, pp. 889P . https://doi.org/10.1093/annonc/mdn524 | viii273
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3062::6c0421e7d03305e6bbc03e75d02df390
https://portal.findresearcher.sdu.dk/da/publications/c7c3b970-a025-11dd-9b31-000ea68e967b
https://portal.findresearcher.sdu.dk/da/publications/c7c3b970-a025-11dd-9b31-000ea68e967b
Publikováno v:
Herrstedt, J, Roila, F, van Belle, S, Bandekar, R R, Levin, J & Grunberg, S M 2008, ' Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) ', Annals of Oncology. Supplement, no. 8, pp. viii 273 . https://doi.org/10.1093/annonc/mdn524
Herrstedt, J, Roila, F, van Belle, S, Bandekar, R R, Levin, J & Grunberg, S M 2008, ' Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) ', International Symposium Supportive Care in Cancer, Houston, United States, 26/06/2008-28/06/2008 .
Herrstedt, J, Roila, F, van Belle, S, Bandekar, R R, Levin, J & Grunberg, S M 2008, ' Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) ', International Symposium Supportive Care in Cancer, Houston, United States, 26/06/2008-28/06/2008 .
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b9caa9cd4a9bc9b939f389be2fc6bbee
https://portal.findresearcher.sdu.dk/da/publications/658b58f0-a028-11dd-9b31-000ea68e967b
https://portal.findresearcher.sdu.dk/da/publications/658b58f0-a028-11dd-9b31-000ea68e967b
Publikováno v:
Hansen, V L, Gabrail, N, Levin, J, Bandekar, R & Herrstedt, J 2008, ' Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial ', ASCO Gastrointestinal Cancers Symposium, Florida, United States, 25/01/2008-27/01/2008 .
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3062::fdc864d4c63c8f75ed0c26618aa73755
https://portal.findresearcher.sdu.dk/da/publications/18b4d7a0-a022-11dd-9b31-000ea68e967b
https://portal.findresearcher.sdu.dk/da/publications/18b4d7a0-a022-11dd-9b31-000ea68e967b
Autor:
Facon, T., Cavo, M., Jakubowiak, A., San Miguel, J., Kumar, S., Orlowski, R.Z., Usmani, S., Palumbo, A., Bandekar, R., Wang, J., Crist, W., O’Rourke, L., Carson, R., Wu, K., Qi, M., Ahmadi, T., Mateos, M.V.
Publikováno v:
In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e294-e295
Publikováno v:
In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e175-e175